Articles From: Concert Pharmaceuticals Presents Positive Data from Multiple Dose Phase 1 Clinical Trial of CTP-354, Lead Candidate for the Treatment of Spasticity to CONCUR TECHNOLOGIES, INC.: Levi & Korsinsky, LLP Announces Investigation of Concur Technologies, Inc. and Its Board of Directors In Connection With the Sale of the Company to SAP SE -- CNQR


Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today Phase 1 data of CTP-354, a novel, potentially first-in-class, non-sedating, once-daily oral treatment for spasticity.
Sign-up for Concert Pharmaceuticals Presents Positive Data from Multiple Dose Phase 1 Clinical Trial of CTP-354, Lead Candidate for the Treatment of Spasticity investment picks
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2014 and provided an update on its pipeline and CTP-354.
Sign-up for Concert Pharmaceuticals Reports Third Quarter 2014 Financial Results and Provides Update on CTP-354 Program investment picks
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the Stifel 2014 Healthcare Conference, November 18, 2014 at 1:50 p.m. EST at The New York Palace Hotel in New York City.
Sign-up for Concert Pharmaceuticals to Present at Stifel 2014 Healthcare Conference on November 18, 2014 investment picks
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2014 financial results on Wednesday, November 12, 2014 before the financial markets open.
Sign-up for Concert Pharmaceuticals to Report Third Quarter 2014 Results on November 12, 2014 investment picks
Concho Resources Inc. (NYSE: CXO) (the “Company” or “Concho”) today announced its upcoming participation at the Executive Oil Conference on Tuesday, November 11 th at 10:30 AM CST, the Bank of America Merrill Lynch 2014 Global Energy Conference on Thursday, November 13 th at 9:00 AM EST, the Ladenburg One-on-One E&P Conference on Wednesday, November 19 th , the Bank of America Merrill Lynch 2014 Leveraged Finance Conference on Tuesday, December 2 nd at 9:30 AM EST, and the Capital One Securities, Inc. 9 th Annual Energy Conference on Thursday, December 11 th at 11:40 AM CST.
Sign-up for Concho Resources Inc. Announces Participation in Upcoming Conferences investment picks
Concho Resources Inc. (NYSE: CXO) (the “Company” or “Concho”) today announced that A.
Sign-up for Concho Resources Inc. Announces Resignation of A. Wellford Tabor from Its Board of Directors investment picks
Concho Resources Inc. (NYSE: CXO) (the “Company” or “Concho”) today reported results for the third quarter of 2014 and provided an outlook for 2015.
Sign-up for Concho Resources Inc. Reports Third Quarter 2014 Results and Provides 2015 Outlook investment picks
--Reiterates FY14 Financial Forecast--
Sign-up for Concord Medical Reports Third Quarter 2014 Financial Results investment picks
Conference call to discuss results will be held on November 18, 2014 BEIJING , Nov.
Sign-up for Concord Medical to Report Third Quarter 2014 Financial Results on November 17, 2014 investment picks
Concordia Healthcare Announces Third Quarter Results - Revenue up 147%, EBITDA up 80% Over Comparative Period Canada NewsWire Third Quarter 2014 Highlights Third quarter, 2014 revenue increase of 147 per cent compared to the third quarter of 2013; Third quarter, 2014 adjusted EBITDA up 137 per cent versus the same period in 2013; On September 30, 2014 , the Company announced its subsidiary, Concordia Pharmaceuticals Inc. (CPI), completed the acquisition of Zonegran® (zonisamide) for commercialization and sale in the United States , including Puerto Rico .
Sign-up for Concordia Healthcare Announces Third Quarter Results - Revenue up 147%, EBITDA up 80% Over Comparative Period investment picks
Concordia Healthcare Corp.
Sign-up for Concordia Healthcare Corp. Provides Clinical Trial and Corporate Update investment picks
TORONTO , Nov.
Sign-up for Concordia Healthcare Corp. Provides Clinical Trial and Corporate Update investment picks
2014/9/23
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Concur Technologies, Inc. NEW YORK , Sept.
Sign-up for CONCUR INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Concur Technologies, Inc. Over the Proposed Sale of the Company to SAP America, Inc. - CNQR investment picks
Partnership helps Japanese companies optimize indirect cost structure to be more competitive TOKYO , Sept.
Sign-up for Concur Japan and ABeam Consulting Launch Strategic Collaboration Covering Indirect Expense Management investment picks
Andrews & Springer LLC , a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against the Board of Directors of Concur Technologies, Inc. (NASDAQ: CNQR) (“Concur” or the “Company”) relating to the sale of the Company to SAP America, Inc., a subsidiary of SAP SE (“SAP”). On September 18, 2014, the two companies announced the signing of a definitive merger agreement pursuant to which SAP will acquire Concur in a merger in a deal worth $8.3 billion.
Sign-up for CONCUR SHAREHOLDER ALERT - Andrews & Springer LLC Is Seeking More Cash for Shareholders of Concur Technologies, Inc. - CNQR investment picks
BELLEVUE, Wash.
Sign-up for Concur Shareholders Approve Acquisition by SAP investment picks
2014/9/19
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Concur Technologies, Inc. (“Concur”) (NasdaqGS: CNQR) concerning the sale to SAP America, Inc., a subsidiary of SAP SE.
Sign-up for CONCUR TECHNOLOGIES SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to SAP investment picks
Shareholder rights law firm Johnson & Weaver, LLP has launched an investigation into whether the board members of Concur Technologies, Inc. (NASDAQ: CNQR) breached their fiduciary duties in connection with the proposed sale of the Company to SAP America, Inc., a subsidiary of SAP SE.
Sign-up for CONCUR TECHNOLOGIES SHAREHOLDER ALERT: Proposed Sale of Concur Technologies, Inc. under Investigation by Johnson & Weaver, LLP in Connection with the Proposed Sale of the Company to SAP SE investment picks
Levi & Korsinsky is investigating the Board of Directors of Concur Technologies, Inc. (“Concur” or the “Company”) (Nasdaq:CNQR) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to SAP America, Inc., a subsidiary of SAP SE (NYSE:SAP). Click here to learn more about the investigation: http://zlk.9nl.com/concur-technologies , or call: 877-363-5972.
Sign-up for CONCUR TECHNOLOGIES, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation of Concur Technologies, Inc. and Its Board of Directors In Connection With the Sale of the Company to SAP SE investment picks
2014/9/25
WILMINGTON, Del.
Sign-up for CONCUR TECHNOLOGIES, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout investment picks
2014/9/20
Rigrodsky & Long, P.A.: Do you own shares of Concur Technologies, Inc. (NASDAQ GS: CNQR )? Did you purchase any of your shares prior to September 18, 2014?
Sign-up for CONCUR TECHNOLOGIES, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout investment picks
2014/9/19
Rigrodsky & Long, P.A.: Do you own shares of Concur Technologies, Inc. (NASDAQ GS: CNQR )? Did you purchase any of your shares prior to September 18, 2014?
Sign-up for CONCUR TECHNOLOGIES, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Concert Pharmaceuticals Presents Positive Data from Multiple Dose Phase 1 Clinical Trial of CTP-354, Lead Candidate for the Treatment of Spasticity to CONCUR TECHNOLOGIES, INC.: Levi & Korsinsky, LLP Announces Investigation of Concur Technologies, Inc. and Its Board of Directors In Connection With the Sale of the Company to SAP SE -- CNQR
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent